Hope for Orphan Drugs in Act

July 2011
Pharmaceutical Representative;Jul2011, Vol. 41 Issue 7, p8
The article discusses the Creating Hope Act of 2011 intended for rare and pediatric orphan diseases in the U.S.


Related Articles

  • EU to provide incentives for 'orphan' drugs. Watson, Rory // BMJ: British Medical Journal (International Edition);05/13/2000, Vol. 320 Issue 7245, p1294 

    Focuses on the legislation introduced by the European Union designed to encourage pharmaceutical companies to develop treatments for orphan diseases. Conditions stated in the legislation; Coverage of the legislation.

  • Finding Homes for Orphan Drugs. Boswell, Clay // Chemical Market Reporter;10/08/2001, Vol. 260 Issue 13, pFR 30 

    Reports that the Orphan Drug Act (ODA) has provided unique opportunities to both pharmaceutical and biotechnology companies in the United States (U.S.). Factors that led to the increase in the number of orphan drugs in the U.S.; What has led some observers to question whether the ODA should be...

  • Topic of the poll.  // BioSpectrum;Nov2014, Vol. 12 Issue 11, p73 

    The article presents poll statistics on the question, is there a need for an Orphan Drug Act.

  • Orphan Drug Act gets a favourable review.  // PharmacoEconomics & Outcomes News;Feb2015, Vol. 722 Issue 1, p24 

    The article reports on the Orphan Drug Act (ODA) and its review based on cost in the U.S.

  • Companies look for profit in orphan drugs. Thompson, Cheryl A. // American Journal of Health-System Pharmacy;11/15/2010, Vol. 67 Issue 22, p1892 

    The article focuses on several pharmaceutical companies and their initiatives related to the development and commercialization of orphan drugs. It says that GlaxoSmithKline established a unit that specializes in drugs for rare diseases. It states that Pfizer Inc. formed the Orphan and Genetic...

  • Marlene Haffner. Goodman, Catherine // Nature Chemical Biology;Dec2006, Vol. 2 Issue 12, p657 

    The article offers a perspective on the influence of the U.S. Orphan Drug Act has had in promoting research on and awareness of rare diseases. The Office of Orphan Product Development has been tasked to administer the Orphan Drug Act for the last 24 years. The Act was inspired by the challenges...

  • Inadequately met needs.  // Nature Biotechnology;May2011, Vol. 29 Issue 5, p371 

    The author asserts that U.S. innovative drug development faces challenges when it comes to chronic diseases. Data from the IMS Institute for Healthcare Informatics show that overall drug spending in the country posted a 1% year-on-year increase for 2009-2010. He adds that the trend in which...

  • 'Orphan Drug Act' Appears to be Working.  // School Health Alert;Dec2012, Vol. 28 Issue 4, p3 

    The article presents a study which examines the effectiveness of the 1983 Orphan Drug Act which was designed to incentivize development among medical advances for the treatment of rare diseases.

  • European Law Prompts Firms to Invest in Rare Disease R&D. Moran, Nuala // BioWorld International;1/5/2011, Vol. 16 Issue 1, p1 

    The article focuses on the investment by companies in rare diseases and the possible creation of a significant number of new companies that focus on researching and developing orphan drugs following the enactment of the European Orphan Drug legislation. An investigation of the impact of the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics